ADMA Biologics, Inc

(NASDAQ:ADMA)

Latest On ADMA Biologics, Inc (ADMA):

Date/Time Type Description Signal Details
2023-05-11 01:31 ESTNewsADMA Biologics GAAP EPS of -$0.03 beats by $0.01, revenue of $57M beats by $3.59MN/A
2023-05-11 01:30 ESTNewsADMA Biologics, Inc. (ADMA) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 23:31 ESTNewsADMA Biologics Q1 2023 Earnings PreviewN/A
2023-03-30 00:16 ESTNewsADMA Biologics: Growth Trends Pointing To ProfitabilityN/A
2023-03-24 06:16 ESTNewsADMA Biologics GAAP EPS of -$0.06 beats by $0.01, revenue of $49.95M beats by $1.88MN/A
2023-03-24 06:16 ESTNewsADMA Biologics expects first-time positive EBITDA by second half of yearN/A
2023-03-24 06:15 ESTNewsADMA Biologics, Inc. (ADMA) Q4 2022 Earnings Call TranscriptN/A
2023-03-22 23:00 ESTNewsADMA Biologics Q4 2022 Earnings PreviewN/A
2023-02-08 18:02 ESTNewsADMA Biocenters receives FDA approval for eighth plasma collection centerN/A
2023-01-17 17:02 ESTNewsADMA Biologics gains as guidance exceeds consensusN/A
2023-01-15 06:00 ESTNewsADMA Biologics: FY22 Numbers Key Inflection PointN/A
2022-12-13 19:01 ESTNewsAdma gets FDA approval for room temperature storage of Asceniv, BivigamN/A
2022-12-08 03:17 ESTNewsADMA Biologics stock dips after pricing ~$60M share offeringN/A
2022-12-07 07:16 ESTNewsADMA Biologics down 7% following stock offeringN/A
2022-11-11 05:31 ESTNewsADMA Biologics hits 52-week high after strong Q3 beatN/A
2022-11-09 19:31 ESTNewsADMA Biologics GAAP EPS of -$0.08 in-line, revenue of $41.09M beats by $6.61MN/A
2022-11-09 19:30 ESTNewsADMA Biologics, Inc. (ADMA) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 01:31 ESTNewsADMA Biologics Q3 2022 Earnings PreviewN/A
2022-10-31 13:46 ESTNewsAdma stock rises on FDA approval of North Carolina-based plasma collection centerN/A
2022-10-24 18:01 ESTNewsAdma Biologics: Understanding The Risks Of Blood Plasma CollectionN/A
2022-08-22 16:50 ESTNewsADMA Biologics: Strong Growth Is Clearing The Path To ProfitabilityN/A
2022-08-11 22:17 ESTNewsADMA Biologics, Inc.'s (ADMA) CEO Adam Grossman on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 22:16 ESTNewsAdma stock rises 10% after Q2 revenue nearly doubles, net loss narrowsN/A
2022-08-11 05:31 ESTNewsADMA Biologics GAAP EPS of -$0.07, revenue of $33.9MN/A
2022-08-11 05:30 ESTNewsADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 17:45 ESTNewsADMA Biologics Q2 2022 Earnings PreviewN/A
2022-06-27 23:02 ESTNewsADMA's 6th plasma collection facility gets FDA approvalN/A
2022-06-21 22:02 ESTNewsADMA biologics to enter Russell 2000 indexN/A
2022-05-13 06:31 ESTNewsADMA Biologics: A Path To Profits Looks ClearN/A
2022-05-12 11:47 ESTNewsADMA Biologics, Inc.'s (ADMA) CEO Adam Grossman on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 18:00 ESTNewsADMA Biologics GAAP EPS of -$0.13 misses by $0.04, revenue of $29.1M beats by $0.95MN/A
2022-05-11 18:00 ESTNewsADMA Biologics up 4% after increasing 2022 revenue guidanceN/A
2022-05-10 22:45 ESTNewsADMA Biologics Q1 2022 Earnings PreviewN/A
2022-04-19 02:16 ESTNewsADMA: Pertinent UpdatesN/A
2022-04-04 13:21 ESTNewsADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-29 21:17 ESTNewsADMA Biologics' 2021 Numbers Showed Continued Strong ExecutionN/A
2022-03-25 12:19 ESTNewsADMA Biologics GAAP EPS of -$0.09 beats by $0.01, revenue of $26.38M beats by $4.61MN/A
2022-03-25 12:19 ESTNewsADMA Biologics up in after-hours trading following quarterly top and bottom line beatsN/A
2022-03-25 12:18 ESTNewsADMA Biologics gets FDA approval to extend shelf life of Asceniv, BivigamN/A
2022-03-24 02:33 ESTNewsADMA Biologics Q4 2021 Earnings PreviewN/A
2022-02-10 22:16 ESTNewsAdma Biologics activist said to support strategic reviewN/A
2022-01-19 08:15 ESTNewsADMA biologics expects record preliminary 4Q and FY21 revenues to be above the consensusN/A
2022-01-18 16:46 ESTNewsADMA Biologics wins FDA nod for its fourth plasma collection centerN/A
2022-01-18 16:46 ESTNewsADMA Biologics: 2021 Was ToughN/A
2021-12-28 22:16 ESTNewsFDA updates EUA for COVID convalescent plasma limiting use to certain patientsN/A
2021-12-09 15:17 ESTNewsADMA Biologics secures new European patent related to S. pneumonia infectionsN/A
2021-11-20 23:16 ESTNewsADMA Biologics: Turning A CornerN/A
2021-11-11 20:31 ESTNewsADMA Biologics raised to Strong Buy at Raymond James citing financial momentumN/A
2021-11-11 00:15 ESTNewsADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-10 01:31 ESTNewsADMA Biologics Q3 2021 Earnings PreviewN/A

About ADMA Biologics, Inc (ADMA):

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

See Advanced Chart

General

  • Name ADMA Biologics, Inc
  • Symbol ADMA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 313
  • Fiscal Year EndDecember
  • IPO Date2013-10-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.admabiologics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 5.32
  • Price/Book (Most Recent Quarter) 3.7
  • Enterprise Value Revenue 7.55
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.17
  • Profit Margin -166%
  • Operating Margin -138%
  • Return on Assets -21%
  • Return on Equity -124%
  • Revenue 40.3 million
  • Earnings Per Share -$1.24
  • Revenue Per Share $0.53
  • Gross Profit -10155155
  • Quarterly Earnings Growth 42.3%
View More

Highlights

  • Market Capitalization 195.71 million
  • EBITDA -52103768
  • Analyst Target Price $8.83
  • Book Value Per Share $0.80
View More

Share Statistics

  • Shares Outstanding 94.55 million
  • Shares Float 76.07 million
  • % Held by Insiders 213%
  • % Held by Institutions 54.51%
  • Shares Short 8.18 million
  • Shares Short Prior Month 8.75 million
  • Short Ratio 1.91
  • Short % of Float 12%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • Beta 1.7
  • 52 Week High $4.2
  • 52 Week Low $1.73
  • 50 Day Moving Average 2.42
  • 200 Day Moving Average 2.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ADMA Biologics, Inc (ADMA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ADMA Biologics, Inc (ADMA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-05$N/A-$0.19-$0.204.04%
2020-06-302020-08-05$N/A-$0.23-$0.16-42.24%
2020-03-312020-05-06$N/A-$0.26-$0.11-128.07%
2019-12-312020-03-12$12.04 million-$0.18-$0.18-0.95%
2019-09-302019-11-06$7.22 million-$0.19-$0.2315.56%
2019-06-302019-08-08$6.56 million-$0.25-$0.2914.65%
2019-03-312019-05-08$3.53 million-$0.28-$0.3211.39%
2018-12-312019-03-13$4.06 million-$0.39-$0.33-17.15%
2018-09-302018-11-08$4.23 million-$0.33-$0.31-6.45%
2018-06-302018-08-10$4.66 million-$0.35-$0.31-11.86%
2018-03-312018-05-14$4.04 million-$0.39-$0.31-26.83%
2017-12-312018-03-05$12 million-$0.24-$0.3938.46%
2017-09-302017-11-03$4.73 million-$0.59-$0.50-18.59%
2017-06-302017-08-11$3.4 million-$0.55-$0.30-84.87%
2017-03-312017-05-12$2.63 million-$0.51-$0.28-80.53%
2016-12-312017-02-24$3.33 million-$0.34-$0.32-5.59%
2016-09-302016-11-10$2.94 million-$0.34-$0.4117.87%
2016-06-302016-08-12$2.27 million-$0.50-$0.38-30.89%
2016-03-312016-05-13$2.12 million-$0.43-$0.442.82%
2015-12-312016-03-23$2.51 million-$0.44-$0.452.22%
2015-09-302015-11-10$1.85 million-$0.48-$0.39-23.08%
2015-06-302015-08-11$1.31 million-$0.44-$0.35-25.71%
2015-03-312015-05-12$1.5 million-$0.37-$0.382.63%
2014-12-312015-03-09$1.49 million-$0.38-$0.380%
2014-09-302014-11-10$1.37 million-$0.36-$0.372.7%
2014-06-302014-08-11$1.5 million-$0.43-$0.5217.31%
2014-03-312014-05-12$1.56 million-$0.64-$0.49-30.61%
2013-12-312014-03-28$425000-$0.54-$0.47-14.89%
2013-09-302013-11-12$1.11 million-$0.29

ADMA Biologics, Inc (ADMA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

ADMA Biologics, Inc (ADMA) Chart:

ADMA Biologics, Inc (ADMA) News:

Below you will find a list of latest news for ADMA Biologics, Inc (ADMA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ADMA Biologics, Inc (ADMA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-04-192.54.15CALL0 20TRUE00
2024-04-1951.15CALL0 5340TRUE00
2024-04-197.50.05CALL0 1850FALSE00
2024-04-19100.03CALL0 140FALSE00
2024-04-192.50PUT0 00FALSE00
2024-04-1950.25PUT0 20FALSE00
2024-04-197.51.53PUT0 261324.74TRUE00
2024-04-19100PUT0 01083.81TRUE00
2024-05-172.53.8CALL0 147259.85TRUE00
2024-05-1751.14CALL20 176165.89TRUE-0.07-0.06
2024-05-177.50.2CALL0 7870FALSE00
2024-05-17100.08CALL0 10FALSE00
2024-05-172.50.15PUT0 450FALSE00
2024-05-1750.1PUT0 1110FALSE00
2024-05-177.51.55PUT0 2879.9TRUE00
2024-05-17100PUT0 0293.4TRUE00
2024-08-162.53.05CALL0 384203.65TRUE00
2024-08-1651.4CALL4 168055.89TRUE1.40
2024-08-167.50.32CALL373 440453.72FALSE0.320
2024-08-16100.15CALL0 100FALSE00
2024-08-162.50.03PUT0 20FALSE00
2024-08-1650.25PUT51 13153.45FALSE0.250
2024-08-167.51.6PUT0 3275.34TRUE00
2024-08-16100PUT0 0116.09TRUE00
2024-11-152.53.75CALL0 20129.45TRUE00
2024-11-1552CALL0 3067.77TRUE00
2024-11-157.50.56CALL0 6749.81FALSE00
2024-11-15100.2CALL0 60FALSE00
2024-11-1512.50CALL0 00FALSE00
2024-11-152.50PUT0 00FALSE00
2024-11-1550.4PUT0 250.93FALSE00
2024-11-157.50PUT0 030.26TRUE00
2024-11-15100PUT0 0103.33TRUE00
2024-11-1512.50PUT0 0138.03TRUE00
2024-12-202.50CALL0 0170.79TRUE00
2024-12-2051.65CALL0 20450.38TRUE00
2024-12-207.50.65CALL0 67952.16FALSE00
2024-12-20100.35CALL0 6548.34FALSE00
2024-12-2012.50CALL0 00FALSE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050.45PUT0 752.65FALSE00
2024-12-207.51.7PUT0 062.74TRUE00
2024-12-20100PUT0 074.72TRUE00
2024-12-2012.50PUT0 0134.76TRUE00
2025-01-172.53.23CALL0 1130.87TRUE00
2025-01-1751.85CALL0 29754.81TRUE00
2025-01-177.50.66CALL0 45762.33FALSE00
2025-01-17100.3CALL0 267450.94FALSE00
2025-01-1712.50.1CALL0 50FALSE00
2025-01-172.50.31PUT0 50FALSE00
2025-01-1750.47PUT0 11754.93FALSE00
2025-01-177.50PUT0 060.17TRUE00
2025-01-17100PUT0 068.95TRUE00
2025-01-1712.50PUT0 0106.26TRUE00

Latest ADMA Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST38$1.905
Jun 13, 2022 7:59 PM EST100$1.905
Jun 13, 2022 7:59 PM EST100$1.905
Jun 13, 2022 7:59 PM EST36$1.905
Jun 13, 2022 7:59 PM EST100$1.9

ADMA Biologics, Inc (ADMA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000713/0001193805-20-000713-index.htm
2019-10-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1368514/000000000019014431/0000000000-19-014431-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000083423720008032/0000834237-20-008032-index.htm
2020-03-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000083423720009209/0000834237-20-009209-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000089924319014466/0000899243-19-014466-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000089924320003914/0000899243-20-003914-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000089924320009225/0000899243-20-009225-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000091957419001192/0000919574-19-001192-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000091957420001141/0000919574-20-001141-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000108514619000734/0001085146-19-000734-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000108514620000752/0001085146-20-000752-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000112329219000868/0001123292-19-000868-index.htm
2019-06-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1368514/000112329219000869/0001123292-19-000869-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1368514/000114036120010160/0001140361-20-010160-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1368514/000114036120010161/0001140361-20-010161-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000119312519040961/0001193125-19-040961-index.htm
2019-05-23SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000119312519154707/0001193125-19-154707-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1368514/000119312520038101/0001193125-20-038101-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001175/0001193805-18-001175-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001198/0001193805-18-001198-index.htm
2018-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001210/0001193805-18-001210-index.htm
2018-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001238/0001193805-18-001238-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001316/0001193805-18-001316-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380518001319/0001193805-18-001319-index.htm
2018-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001425/0001193805-18-001425-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001429/0001193805-18-001429-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380518001431/0001193805-18-001431-index.htm
2019-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000012/0001193805-19-000012-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000026/0001193805-19-000026-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000090/0001193805-19-000090-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000091/0001193805-19-000091-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000092/0001193805-19-000092-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000098/0001193805-19-000098-index.htm
2019-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000160/0001193805-19-000160-index.htm
2019-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000246/0001193805-19-000246-index.htm
2019-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000251/0001193805-19-000251-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000254/0001193805-19-000254-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000280/0001193805-19-000280-index.htm
2019-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1368514/000119380519000281/0001193805-19-000281-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000292/0001193805-19-000292-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000293/0001193805-19-000293-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000294/0001193805-19-000294-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000295/0001193805-19-000295-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000296/0001193805-19-000296-index.htm
2019-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000297/0001193805-19-000297-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000301/0001193805-19-000301-index.htm
2019-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000332/0001193805-19-000332-index.htm
2019-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000339/0001193805-19-000339-index.htm
2019-04-05PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000346/0001193805-19-000346-index.htm
2019-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000366/0001193805-19-000366-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000415/0001193805-19-000415-index.htm
2019-05-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000441/0001193805-19-000441-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000454/0001193805-19-000454-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380519000455/0001193805-19-000455-index.htm
2019-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000470/0001193805-19-000470-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000490/0001193805-19-000490-index.htm
2019-05-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1368514/000119380519000492/0001193805-19-000492-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000496/0001193805-19-000496-index.htm
2019-05-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1368514/000119380519000498/0001193805-19-000498-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000520/0001193805-19-000520-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000521/0001193805-19-000521-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000522/0001193805-19-000522-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000523/0001193805-19-000523-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000524/0001193805-19-000524-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000525/0001193805-19-000525-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000540/0001193805-19-000540-index.htm
2019-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000559/0001193805-19-000559-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000561/0001193805-19-000561-index.htm
2019-06-128-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000569/0001193805-19-000569-index.htm
2019-07-01PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000614/0001193805-19-000614-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000621/0001193805-19-000621-index.htm
2019-07-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000637/0001193805-19-000637-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000714/0001193805-19-000714-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380519000715/0001193805-19-000715-index.htm
2019-08-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000761/0001193805-19-000761-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000774/0001193805-19-000774-index.htm
2019-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000798/0001193805-19-000798-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000839/0001193805-19-000839-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000887/0001193805-19-000887-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000893/0001193805-19-000893-index.htm
2019-10-04S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1368514/000119380519000903/0001193805-19-000903-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519000905/0001193805-19-000905-index.htm
2019-10-07424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1368514/000119380519000907/0001193805-19-000907-index.htm
2019-10-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001327/0001193805-19-001327-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001351/0001193805-19-001351-index.htm
2019-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001355/0001193805-19-001355-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001361/0001193805-19-001361-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001396/0001193805-19-001396-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380519001398/0001193805-19-001398-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001423/0001193805-19-001423-index.htm
2019-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001461/0001193805-19-001461-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380519001941/0001193805-19-001941-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000010/0001193805-20-000010-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000024/0001193805-20-000024-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000033/0001193805-20-000033-index.htm
2020-02-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520000106/0001193805-20-000106-index.htm
2020-02-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520000109/0001193805-20-000109-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000110/0001193805-20-000110-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000127/0001193805-20-000127-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000129/0001193805-20-000129-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000131/0001193805-20-000131-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000133/0001193805-20-000133-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000135/0001193805-20-000135-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000138/0001193805-20-000138-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000139/0001193805-20-000139-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000259/0001193805-20-000259-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000285/0001193805-20-000285-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000286/0001193805-20-000286-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000287/0001193805-20-000287-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000288/0001193805-20-000288-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000289/0001193805-20-000289-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000290/0001193805-20-000290-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000291/0001193805-20-000291-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000292/0001193805-20-000292-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000293/0001193805-20-000293-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000300/0001193805-20-000300-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1368514/000119380520000348/0001193805-20-000348-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000349/0001193805-20-000349-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000377/0001193805-20-000377-index.htm
2020-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000452/0001193805-20-000452-index.htm
2020-04-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000474/0001193805-20-000474-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000502/0001193805-20-000502-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000529/0001193805-20-000529-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000548/0001193805-20-000548-index.htm
2020-05-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000549/0001193805-20-000549-index.htm
2020-05-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000550/0001193805-20-000550-index.htm
2020-05-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000551/0001193805-20-000551-index.htm
2020-05-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000552/0001193805-20-000552-index.htm
2020-05-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000553/0001193805-20-000553-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000561/0001193805-20-000561-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520000562/0001193805-20-000562-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000618/0001193805-20-000618-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000638/0001193805-20-000638-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000710/0001193805-20-000710-index.htm
2020-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000712/0001193805-20-000712-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000713/0001193805-20-000713-index.htm
2020-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000770/0001193805-20-000770-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520000957/0001193805-20-000957-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520000960/0001193805-20-000960-index.htm
2020-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520000961/0001193805-20-000961-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001003/0001193805-20-001003-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001004/0001193805-20-001004-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001005/0001193805-20-001005-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001023/0001193805-20-001023-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001036/0001193805-20-001036-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001069/0001193805-20-001069-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001111/0001193805-20-001111-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001128/0001193805-20-001128-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001129/0001193805-20-001129-index.htm
2020-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001135/0001193805-20-001135-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001139/0001193805-20-001139-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1368514/000119380520001390/0001193805-20-001390-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520001392/0001193805-20-001392-index.htm
2020-11-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1368514/000119380520001393/0001193805-20-001393-index.htm
2019-10-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1368514/999999999519002318/9999999995-19-002318-index.htm
2018-09-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1368514/999999999718008174/9999999997-18-008174-index.htm
2019-04-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1368514/999999999719002962/9999999997-19-002962-index.htm
2020-02-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1368514/999999999720000431/9999999997-20-000431-index.htm
2020-02-10SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1368514/999999999720000623/9999999997-20-000623-index.htm

ADMA Biologics, Inc (ADMA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ADMA Biologics, Inc (ADMA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 213%
Institutional Ownership: 5451%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-05-17Jerrold B GrossmanDirectorBuy12,000.004.0048,000.00110,007.00https://www.sec.gov/Archives/edgar/data/1368514/000119380519000524/0001193805-19-000524-index.htm
2019-05-21PERCEPTIVE ADVISORS LLC10% Share HolderBuy4,000,000.004.0016,000,000.0011,521,102.00https://www.sec.gov/Archives/edgar/data/1368514/000089924319014466/0000899243-19-014466-index.htm
2020-02-11Jerrold B GrossmanDirectorBuy22,857.003.5079,999.50132,864.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000131/0001193805-20-000131-index.htm
2020-02-28Jerrold B GrossmanDirectorBuy7,500.00140,364.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000288/0001193805-20-000288-index.htm
2020-08-12Jerrold B GrossmanDirectorBuy200.002.87574.00140,564.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001023/0001193805-20-001023-index.htm
2020-08-12Jerrold B GrossmanDirectorBuy5,000.002.8914,450.00145,564.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001023/0001193805-20-001023-index.htm
2020-08-12Jerrold B GrossmanDirectorBuy5,000.002.9014,475.00150,564.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001023/0001193805-20-001023-index.htm
2020-08-21Jerrold B GrossmanDirectorBuy5,000.002.5612,800.00155,564.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001069/0001193805-20-001069-index.htm
2020-08-21Jerrold B GrossmanDirectorBuy300.002.62786.00155,864.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001069/0001193805-20-001069-index.htm
2020-02-11PERCEPTIVE ADVISORS LLC10% Share HolderBuy4,563,700.003.5015,972,950.0016,084,802.00https://www.sec.gov/Archives/edgar/data/1368514/000089924320003914/0000899243-20-003914-index.htm
2020-09-10Jerrold B GrossmanDirectorBuy5,000.002.2211,100.00160,864.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001135/0001193805-20-001135-index.htm
2020-03-19PERCEPTIVE ADVISORS LLC10% Share HolderBuy500,000.002.101,050,000.0016,584,802.00https://www.sec.gov/Archives/edgar/data/1368514/000089924320009225/0000899243-20-009225-index.htm
2020-02-28Adam S GrossmanPresident and CEOBuy100,000.00166,098.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000287/0001193805-20-000287-index.htm
2020-08-10Adam S GrossmanPresident and CEOBuy10.003.0630.60166,108.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001005/0001193805-20-001005-index.htm
2020-08-10Adam S GrossmanPresident and CEOBuy2,990.003.079,179.30169,098.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001005/0001193805-20-001005-index.htm
2020-08-10Adam S GrossmanPresident and CEOBuy2,000.003.046,080.00171,098.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001005/0001193805-20-001005-index.htm
2020-08-11Adam S GrossmanPresident and CEOBuy1,000.002.972,970.00172,098.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001005/0001193805-20-001005-index.htm
2020-09-08Adam S GrossmanPresident and CEOBuy4,000.002.248,959.60176,098.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001128/0001193805-20-001128-index.htm
2019-05-17James MondEVP, CSO and CMOBuy4,500.004.0018,000.0017,889.00https://www.sec.gov/Archives/edgar/data/1368514/000119380519000522/0001193805-19-000522-index.htm
2020-08-13MARTHA J DEMSKIDirectorBuy2,000.002.885,760.002,000.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001036/0001193805-20-001036-index.htm
2020-02-11James MondCSO and CMOBuy4,285.003.5014,997.5022,174.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000133/0001193805-20-000133-index.htm
2020-02-11Jerrold B GrossmanDirectorBuy22,857.003.5079,999.5022,857.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000131/0001193805-20-000131-index.htm
2019-05-17BRIAN LENZEVP, CFOBuy5,000.004.0020,000.0025,000.00https://www.sec.gov/Archives/edgar/data/1368514/000119380519000521/0001193805-19-000521-index.htm
2020-02-11BRIAN LENZEVP, CFOBuy7,142.003.5024,997.0032,142.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000129/0001193805-20-000129-index.htm
2019-05-17Adam S GrossmanPresident and CEOBuy5,000.004.0020,000.0037,527.00https://www.sec.gov/Archives/edgar/data/1368514/000119380519000520/0001193805-19-000520-index.htm
2020-09-11MARTHA J DEMSKIDirectorBuy2,200.002.295,038.004,200.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001139/0001193805-20-001139-index.htm
2019-06-06Biotest Divestiture Trust10% Share HolderSell5,813,954.003.7521,802,327.504,295,580.00https://www.sec.gov/Archives/edgar/data/1368514/000112329219000868/0001123292-19-000868-index.htm
2020-02-28ERIC I RICHMANDirectorBuy7,500.0044,030.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000290/0001193805-20-000290-index.htm
2019-05-17Lawrence P. GuiheenDirectorBuy25,000.004.00100,000.0050,000.00https://www.sec.gov/Archives/edgar/data/1368514/000119380519000523/0001193805-19-000523-index.htm
2020-02-28James MondEVP, CSO and CMOBuy40,000.0062,174.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000285/0001193805-20-000285-index.htm
2020-02-11Adam S GrossmanPresident and CEOBuy28,571.003.5099,998.5066,098.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000127/0001193805-20-000127-index.htm
2020-08-10James MondEVP, CSO and CMOBuy5,000.002.8814,400.0067,174.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001003/0001193805-20-001003-index.htm
2020-08-10James MondEVP, CSO and CMOBuy2,000.002.885,750.0069,174.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001003/0001193805-20-001003-index.htm
2020-02-11Lawrence P. GuiheenDirectorBuy20,000.003.5070,000.0070,000.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000135/0001193805-20-000135-index.htm
2020-02-28BRIAN LENZEVP, CFOBuy40,000.0072,142.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000286/0001193805-20-000286-index.htm
2020-09-08James MondEVP, CSO and CMOBuy4,000.002.208,800.0073,174.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001129/0001193805-20-001129-index.htm
2020-02-28Bryant FongDirectorBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000293/0001193805-20-000293-index.htm
2020-02-28DOV A MD GOLDSTEINDirectorBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000291/0001193805-20-000291-index.htm
2020-02-28STEVE ELMSDirectorBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000292/0001193805-20-000292-index.htm
2020-08-11BRIAN LENZEVP, CFOBuy4,000.002.9711,860.0076,142.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520001004/0001193805-20-001004-index.htm
2020-02-28Lawrence P. GuiheenDirectorBuy7,500.0077,500.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000289/0001193805-20-000289-index.htm
2019-05-17Adam S GrossmanPresident and CEOBuy25,000.004.00100,000.00821,301.00https://www.sec.gov/Archives/edgar/data/1368514/000119380519000520/0001193805-19-000520-index.htm
2020-02-11Adam S GrossmanPresident and CEOBuy57,143.003.50200,000.50878,444.00https://www.sec.gov/Archives/edgar/data/1368514/000119380520000127/0001193805-20-000127-index.htm